Matthew Zirwas, MD

At RAD 2025, Matthew Zirwas, MD, outlined 2 upcoming shifts in dermatology: the emergence of povorcitinib for hidradenitis suppurativa and the anticipated generic availability of tofacitinib.

At RAD 2025, Matthew Zirwas, MD, explored the distinct clinical profiles of IL-31 and IL-13 inhibitors, highlighting nemolizumab’s potential superiority for itch relief.

His presentation at South Beach Symposium will feature Zirwas’ insights on JAK inhibitors, eczema treatments, and emerging therapies.

Dermatology Times staff will be onsite covering SBS 2025 with expert insights, interviews, and breaking news.

We want to know: Will you be attending the symposium in Miami Beach this week?

A panelist discusses how recent innovations in topical cream formulations for atopic dermatitis have led to improved efficacy, better tolerability, and enhanced quality of life for patients.

A panelist discusses how combining different therapeutic approaches, such as topical agents with systemic medications, can provide optimal control for patients with severe atopic dermatitis while managing both acute flares and long-term disease maintenance.

A panelist discusses how health care providers can address patients’ concerns about topical treatment side effects in atopic dermatitis by providing education about proper application, expected outcomes, and the strong safety profile of modern topical medications.

A panelist discusses how the choice between systemic and topical treatments for atopic dermatitis patients should be based on factors like disease severity, affected body surface area, impact on quality of life, and previous treatment response.

Chronic hand eczema poses diagnostic and treatment challenges due to its multifaceted etiology. New therapies like JAK inhibitors offer hope.

Zirwas spoke with Dermatology Times to share the top clinical pearls and key takeaways from his discussion on contact dermatitis.

Zirwas presented 2 sessions at SDPA on innovative care strategies for patients with AD and other itch-related diseases.

Click here to test your knowledge and read more about the treatment landscape of chronic hand eczema.

During an interview with Dermatology Times, Zirwas outlined modern allergens such as sulfites, dietary nickel, and acrylates.

From dupilumab to OX40s, Zirwas talked about the niche to all atopic dermatitis therapies to make the best decision with your patient.

In a session at Maui Derm NP+PA Fall, Zirwas talked about the newfound discoveries of causation within the AD space.

Matthew Zirwas, MD, hosted a Case-Based Roundtable discussion to review 2 challenging cases of atopic dermatitis involving intense itch and severe hand dermatitis.

Linda Stein Gold, MD, and Matthew Zirwas, MD, share some advice for clinicians on how to discuss JAK inhibitors with patients.

Dr Matthew Zirwas describes his experience using JAK inhibitor ruxolitinib in his clinical practice.

Clinicians provide insight into the risk of high systemic absorption levels with JAK inhibitor treatments.

Matthew Zirwas, MD, breaks down the safety of JAK inhibitors based on clinical trial data.

Key opinion leaders explain the box warnings and safety profiles of JAK inhibitors.

Linda Stein Gold, MD, provides an overview of the four JAK inhibitors currently available for treating inflammatory diseases.